The FDA approved AbbVie’s Mavyret to treat adults with hepatitis C genotypes 1 through 6 without cirrhosis or with mild cirrhosis, including those who failed previous direct-acting antiviral treatment, according to an agency press release. The new approval indicates only 8 weeks of treatment needed in treatment-naive patients without cirrhosis.
This is the same drug recently discussed in the EU and named Maviret.
The FDA approved AbbVie’s Mavyret to treat adults with hepatitis C genotypes 1 through 6 without cirrhosis or with mild cirrhosis, including those who failed previous direct-acting antiviral treatment, according to an agency press release. The new approval indicates only 8 weeks of treatment needed in treatment-naive patients without cirrhosis.
This is the same drug recently discussed in the EU and named Maviret.
Healio Release - Mavyret